Analyst Upgrades

• FBR Capital upgraded Microsoft (MSFT) to outperform from market perform, citing valuation and the ongoing corporate PC cycle refresh. The firm upped its target for shares to $32 from $31.
• Oppenheimer upgraded BP (BP) to outperform from perform with a $55 price target as it sees greater upside potential than downside risk from the oil spill.
• Wunderlich upgraded Stericycle (SRCL) to hold from sell and raised its target for shares to $50 from $42, citing the company's alliance with Republic Services (RSG).
• Illinois Tool Works (ITW) was upgraded to overweight from equal weight at Barclays.
• GameStop (GME) was upgraded to buy from neutral at Janney Montgomery.
• Fluor (FLR) was upgraded to buy from neutral at Goldman.

Analyst Upgrades

• JPMorgan upgraded Anadarko Petroleum (APC) to overweight from neutral on valuation as it views the recent pullback in shares as excessive. Despite upgrading, the firm lowered its target for shares to $82 from $90.
• Oppenheimer upgraded Office Depot (ODP) to perform from underperform and upped its target for shares to $7 from $3 after raising its estimates for companies in the Office Products Retail space. The firm expects trends to accelerate for the sector due to moderating unemployment pressures. In conjunction with the upgrade, Opco raised its target for OfficeMax (OMX) to $26 from $21 and target for Staples (SPLS) to $30 from $28. Both stocks remain outperform rated.
• C.K. Cooper upgraded iRobot (IRBT) to buy from hold with a $30 price target following the company's analyst day.
• Seadrill (SDRL) was upgraded to buy from hold at Jefferies.
• Vodafone (VOD) was upgraded to neutral from reduce at Nomura.

Merit Medical Systems (NASDAQ: MMSI) develops and manufactures proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology and radiology. Offerings include the catheters, guide wires, inflation devices, needles, and tubing used in heart stent procedures, pacemaker placements, and angioplasties. As well, Merit makes products for endoscopy, dialysis, and other therapeutic and diagnostic procedures. Boston Scientific (NYSE: BSX) and Johnson & Johnson (NYSE: JNJ) are major competitors.

The firm pleased investors last week, when it guided Q2 EPS to 19-21 cents and Q2 revenues to about $57.4 million. Analysts had been expecting 16 cents and $55.77 million. Gross margins for the quarter were estimated at 42.7%, which would be a 500 basis point improvement from Q2'07. CL King subsequently upgraded the shares to "accumulate".